Clinical Trials Unit at Kennedy Krieger Institute

Breaking New Ground In The Treatment of Childhood Developmental Disorders

Clinical Trials Unit at Kennedy Krieger Institute brings together patients and families, research scientists and private industry to find new ways to treat, cure and prevent genetic and developmental disorders.

Clinical Trials Unit at Kennedy Krieger Institute offers you an opportunity to receive the very best of care from top professionals, while gaining access to new treatments designed to make a difference in your quality of life. Participating in a clinical trial can change not only your life, but the lives of children around the world.

Participate In Clinical Research at Kennedy Krieger

Clinical trials at Kennedy Krieger Institute are unique, because we specialize in preventing and treating disorders of the brain, spinal cord, and musculoskeletal system. Our scientists and researchers have deep knowledge about the disorders they are treating, each having devoted their careers to the disorder's study and treatment.

Led by Dr. Robert FindlingDr. Michael JohnstonDr. Tanjala Gipson, and Dr. Dejan Budimirovic, the Clinical Trials Unit is composed of research managers, nurses, coordinators, and administrators who have work as a coordinated and effective team. For us, the patient comes first:

  • All research is undertaken with the upmost care and concern for the patient's and family's safety, health, confidentiality and privacy.
  • Each study follows federal guidelines regulating clinical research.
  • Each study is painstakingly reviewed by panels of peers and community members to ensure it is designed to produce positive, effective outcomes for patients and for the research community. 
  • Each patient participating in a study receives expert assessment, careful screening and diligent monitoring through the entire course of treatment.

Please contact us by email or phone (see below), so we can be in touch about studies that would be a good fit for your child.

Currently Recruiting Trials

The following studies are currently accepting new participants:

Children ages 1 - 9.99 years of age with MECP2 Mutation

Children with Tuberous Sclerosis Complex, autism, and seizures,
Ages 4-15

Men with Autism Spectrum Disorder, Ages 18 - 45

Tuberous Sclerosis Complex (TSC) Patients of All Ages with Visible
Facial Angiofibromas

Adolescents with Major Depressive Disorder (MDD), Ages 12-17

Children with Anxiety or Depression, Ages 7-17 years

Adolescents with a Mental Illness, Ages 12-17

Children Receiving Psychotherapy in an Outpatient Setting and/or Have Recently Been Prescribed Sertraline, Ages 6-14

Adolescents with Major Depressive Disorder, ages 12 - 17

Children and adolescents with neurodevelopmental disabilities and sleep problems, ages 2 - 17.5

Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

Children with Attention Deficit Hyperactivity Disorder (ADHD), ages 6 - 12

Children and adolescents with or without Attention Deficit Hyperactivity Disorder (ADHD), ages 6 - 17

Many studies for a range of diagnoses and disorders will be approved in the near future. To ensure you are among the first to learn of new studies when they open, please contact us by email or phone.

For more information, please contact the group at 443-923-3850 or